Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:adjuvant |
gptkb:AS03
|
| gptkbp:antigen |
recombinant SARS-CoV-2 spike protein
|
| gptkbp:brand |
gptkb:Skycovione
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:countryOfOrigin |
gptkb:South_Korea
|
| gptkbp:developer |
gptkb:SK_Bioscience
GlaxoSmithKline |
| gptkbp:dosing_schedule |
two doses, 4 weeks apart
|
| gptkbp:effect |
demonstrated in clinical trials
|
| gptkbp:first_approval_date |
June 2022
|
| gptkbp:fundedBy |
gptkb:Coalition_for_Epidemic_Preparedness_Innovations
|
| https://www.w3.org/2000/01/rdf-schema#label |
GBP510 COVID-19 vaccine
|
| gptkbp:marketedAs |
gptkb:Skycovione
|
| gptkbp:regulates |
gptkb:South_Korea_Ministry_of_Food_and_Drug_Safety
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:storage_temperature |
2–8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
protein subunit vaccine
|
| gptkbp:WHO_emergency_use_listing |
2022
|
| gptkbp:bfsParent |
gptkb:SK_Bioscience
|
| gptkbp:bfsLayer |
6
|